Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer.

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Abstract Text:

Yuichiro Tanaka,Hiroshi Hirata,Zhong Chen,Nobuyuki Kikuno,Ken Kawamoto,Shahana Majid,Takashi Tokizane,Shinji Urakami,Hiroaki Shiina,Koichi Nakajima,Rajiv Dhir,Rajvir Dahiya,

The estrogen metabolite, 4-hydroxy-estrogen, has been shown to play a role in malignant transformation of male kidneys. To counteract the effects of this catechol-estrogen, the catechol-O-methyltransferase (COMT) enzyme is capable of neutralizing the genotoxic effects of this compound. A polymorphic variant of COMT has been shown to have a reduced enzyme activity, and thus, we hypothesize that single nucleotide polymorphisms of the COMT gene can be a risk factor for renal cell cancer (RCC). To determine this hypothesis, a study of a Japanese male population was used and the genetic distributions of COMT polymorphisms at codons 62 (C-->T), 72 (G-->T), and 158 (G-->A) were analyzed in 157 normal healthy subjects and 123 sporadic RCC (clear cell type) samples by using a sequence-specific PCR technique. These experiments show that the variant genotype (P = 0.025) and allele (P = 0.011) at codon 62 is a risk factor for RCC. The odds ratio and 95% confidence interval for cancer were 3.16 and 1.29 to 7.73, respectively, for the T/T genotype as compared with wild-type. No associations for renal cancer were found at either codons 72 or 158 in this Japanese male population. However, codons 62 and 158 were observed to be in linkage disequilibrium, and haplotype analysis shows the combined forms of T-A, T-G, and C-A to be associated with RCC as compared with C-G (P < 0.001). When evaluating the risk of COMT polymorphisms with grade of cancer, no associations were observed for any of the genotypes. This study is the first to report COMT polymorphism to be associated with RCC. These results are important in understanding the role of COMT polymorphisms in the pathogenesis of RCC.

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Publishing Authors By Initials

Y Tanaka,H Hirata,Z Chen,N Kikuno,K Kawamoto,S Majid,T Tokizane,S Urakami,H Shiina,K Nakajima,R Dhir,R Dahiya,

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research

PUBMED ID PMID:

MEDLINE DATE:

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Cancer epidemiology, biomarkers & prevention : a p

VOLUME: 16

Page Numbers: 92-7

Journal Abbreviation: Cancer Epidemiol. Biomarkers P

ISSN: 1055-9965

DAY: 3

MONTH: Jan

YEAR: 2007

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9200608

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: genetics

Chemical & Substance for Abstract: Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer. Information

Substance Name: Catechol O-Methyltransferase

Registry Number: EC 2.1.1.6

Grant and Affiliation Information for Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer.

AFFILIATION: Department of Urology, Veterans Affairs Medical Center and University of California at San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA.

Country: United States

AGENCY: United States NIDDK

GRANT: T32 DK07790

ACRONYM: DK

MEDLINETA: Cancer Epidemiol Biomarkers Pr

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer Related Publications

• A dioxin-responsive enhancer 3' of the human CYP1A2 gene.
• Basal cell carcinoma with pulmonary and lymph node metastasis causing death.
• COD and BOD removal from domestic wastewater generated in decentralised sectors.
• COMT polymorphisms affecting protein expression are risk factors for endometrial cancer.
• CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.
• Chromatin changes on the GSTP1 promoter associated with its inactivation in prostate cancer.
• DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
• Effect of delignification pretreatment and selective enrichment on methane production from cattle waste.
• Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.
• Erythematous pedunculated papule on a 29-year-old man--quiz case.
• GGC and StuI polymorphism on the androgen receptor gene in endometrial cancer patients.
• Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
• Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.
• Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.
• Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
• MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
• MicroRNA-373 induces expression of genes with complementary promoter sequences.
• Mismatch Repair Gene MSH3 Polymorphism is Associated With the Risk of Sporadic Prostate Cancer.
• Polymorphisms of DNA repair genes are risk factors for prostate cancer.
• Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer.
• Synthesis of a phenylalanine-rich peptide as potential anthelmintic and cytotoxic agent.
• Total synthesis and biological potential of psammosilenin a.
• Transformation of Progesterone by Traemetes hispida.
• Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.